Loading
Genfit Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest was filed 11 Jul 2023.
Genfit: what insiders have been doing
Genfit, classified in the Healthcare & Pharma sector, is a listed company based in Loos, France, founded in 1999. Its insiders report their share dealings to AMF. In the past year (18 October 2025 to 18 October 2026), 1 filing came from 1 insider.
The filings describe grants, exercises and other transfers rather than trades on the open market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Compared with its exchange (316 companies, median 6 filings), a count of 1 filing is below the norm. Looking back to 2022, when coverage begins, insiders filed 6 purchases and no sales.
There has been no open-market purchase by an insider of Genfit for at least a year.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from AMF disclosures alone and does not predict where the share price will go.
Key facts
Headquarters: Loos, France · Founded: 1999
Source: Wikidata (CC0).
Insider Decl.
9
Thresholds
n/a
Buy Volume
€181,391
6 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- +9.5%Entry €3.72 · Close at T+365 €4.07
- +9.5%Entry €3.67 · Close at T+365 €4.02
- +9.5%Entry €3.67 · Close at T+365 €4.02
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Genfit Strong Buy (bullish), based on 5 analysts. Average price target: €17.48.
Financial data
as of FY 2025FY ended December 2025 · cache
€9.30
Analyst consensus
5 analystsStrong buy
€15.00Target €17.48(+88%)€22.40
Income statement
Revenue€65.4M
Gross profit€65.1M100% margin
EBITDA-€83.5M-128% margin
Net income-€86.0M-169.6% margin
Valuation
PER (forward)99.5x
Beta1.10
Balance sheet & cash
Market cap€465.9M
Total debt€150.7M
Free Cash Flow-€29.7M
Profitability & ownership
ROE-5189.6%
ROA-21.1%
% insiders13.2%
% institutions14.2%
Last declaration on 4 March 2026
Declarations9 total
28,958 shares@ €3.08050.013% mcap100.0% of flowOption d'achatEuronext ParisISIN FR00041631112026DD1098600
5,300 shares@ €3.67750.9% of flowActionEuronext ParisISIN FR00041631112023DD918885
Canonical exit: 5 Oct 2023 (T+90)
10,000 shares@ €3.706151.5% of flowActionEuronext ParisISIN FR00041631112023DD918358
Canonical exit: 3 Oct 2023 (T+90)
10,000 shares@ €3.69651.9% of flowActionEuronext ParisISIN FR00041631112023DD918364
Canonical exit: 4 Oct 2023 (T+90)
5,300 shares@ €3.541549.1% of flowActionEuronext ParisISIN FR00041631112023DD917873
Canonical exit: 1 Oct 2023 (T+90)
4 shares0ActionEuronext ParisISIN FR00041631112022DD864906
2,000 shares0ActionEuronext ParisISIN FR00041631112022DD864869
10,000 shares@ €3.4248.1% of flowActionEuronext ParisISIN FR00041631112022DD824658
Canonical exit: 31 May 2022 (T+90)
10,000 shares@ €3.491248.5% of flowActionEuronext ParisISIN FR00041631112022DD824665
Canonical exit: 1 Jun 2022 (T+90)
9 of 9 declarations
About Genfit
Genfit is a French biopharmaceutical company listed on Euronext Paris under the ticker GNFT and identified by ISIN FR0004163111. Founded in 1999 in France by Jean-François Mouney, now Chairman of the Board, the company has built its identity around long-standing expertise in liver diseases, with a particular emphasis on rare and severe conditions with major unmet medical needs. Its headquarters are in Loos, near Lille, and the group also maintains operations in Cambridge, Massachusetts, and Zurich, Switzerland. Over time, Genfit has evolved from a research-focused organization into a late-stage biopharmaceutical company with a diversified R&D portfolio. Historically, the company has also demonstrated an ability to create value through strategic collaborations and licensing agreements with major pharmaceutical players, reflecting its track record in advancing programs and monetizing assets beyond internal development.
Genfit’s core business is now centered on rare and life-threatening liver diseases, with a strategic emphasis on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes multiple assets under development, built around complementary mechanisms of action and different routes of administration. In parallel, the company is pursuing additional programs in severe indications such as cholangiocarcinoma, urea cycle disorders, and certain organic acidemias. Genfit also develops non-invasive diagnostic solutions, notably technologies aimed at detecting MASH/NASH and ammonia-related disorders, strengthening its value proposition across the full care pathway of liver disease management. The group has shown it can advance drug candidates from early discovery into late-stage clinical development and pre-commercialization, highlighted by the success of the Phase 3 ELATIVE study of elafibranor in Primary Biliary Cholangitis.
Read moreShow less
From a market and financial perspective, Genfit is positioned as a specialist niche player with strong scientific credibility and exposure to high-value medical and economic opportunities. The company has recently reinforced its international footprint and financial flexibility, notably through non-dilutive funding arrangements and revenues tied to partnerships. Its transatlantic geographic presence enables it to combine European scientific capabilities with access to the U.S. market and key biotech ecosystems. As such, Genfit remains a growth-oriented healthcare stock whose performance is closely linked to clinical execution, regulatory milestones, and the monetization of its therapeutic and diagnostic pipeline.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
